American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 719-723 , May 2008

Efficacy and Safety of Fondaparinux and Enoxaparin for Acute Coronary Syndromes in CKD

  • Donald F. Brophy, PharmD, MSc, BCPS

      Affiliations

    • Corresponding Author InformationAddress correspondence to Donald F. Brophy, PharmD, MSc, FCCP, BCPS, Associate Professor of Pharmacy and Internal Medicine (Nephrology), Director, Coagulation Special Studies Laboratory, Department of Pharmacy, Virginia Commonwealth University/Medical College of Virginia Campus, PO Box 980533, Richmond, VA 23298-0533.

References 

  1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. AHA scientific statement: Kidney disease as a risk factor for development of cardiovascular disease (A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention). Circulation. 2003;108:2154–2169
  2. US Renal Data Systems. Morbidity and mortality, in USRDS 2006 Annual Data Report. Am J Kidney Dis. 2007;49(suppl 1):S130–S146
  3. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673–684
  4. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33–41
  5. SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54
  6. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–1840
  7. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. [erratum in N Engl J Med 350:423, 2004] N Engl J Med. 2003;349:1695–1705
  8. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med. 2004;140:867–873
  9. Simoons ML, Bobbink IWG, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol. 2004;43:2183–2219
  10. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial. Circulation. 2005;111:1390–1397
  11. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  12. Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007;147:304–310
  13. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43:586–590
  14. Khazan M, Scheuering S, Adamson R, Mathis AS. Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. Pharmacotherapy. 2003;23:651–658
  15. Macie C, Forbes L, Foster GA, Douketis JD. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004;125:1616–1624
  16. Peng YG, Eikelboom JW, Tenni P, McQuillan A, Thom J. Renal function, peak anti-Xa levels and enoxaparin dosing. J Pharm Pract Res. 2004;34:14–17
  17. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: A comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125:856–863
  18. Bazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116:41–50
  19. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753–759
  20. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J. 2004;148:582–589
  21. Green B, Greenwood M, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol. 2005;59:281–290
  22. Collet JP, Montalescot F, Fine E. Enoxaparin in unstable angina patients who would have been excluded from randomized clinical trials. J Am Coll Cardiol. 2003;41:8–14
  23. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 2001;80:81–82(letter)
  24. Sanofi-Aventis Pharmaceuticals. Lovenox (enoxaparin sodium) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals; 2006;

 Originally published online as doi:10.1053/j.ajkd.2008.02.002 on March 31, 2008.

PII: S0272-6386(08)00165-0

doi: 10.1053/j.ajkd.2008.02.002

American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 719-723 , May 2008

Article Tools